0 1 min 6 mths

When Biological E was tasked with responding to the Covid outbreak and developing a vaccine, the aim was on making the vaccine effective, safe, and economical, as many countries’ health budgets were severely taxed.
“We chose the vaccine platform that we did, which is the recombinant subunit – of course because a lot of our experience with Hepatitis B vaccine with several hundred million doses supplied, both individually and in the form of a pentavalent and the large-scale infrastructure that supports it,” Mahima Datla, MD, Biological E, said during a panel discussion on the first day of BioAsia titled “Two years into the pandemic – Challenge

Leave a Reply

Your email address will not be published.